The AlphaLISA™ SureFire® Ultra™ Human and Mouse Total LATS1 assay is a sandwich immunoassay for quantitative detection of total LATS1 in cellular lysates using Alpha Technology.
| Feature | Specification |
|---|---|
| Application | Cell Signaling |
| Protocol Time | 2h at RT |
| Sample Volume | 10 µL |
The AlphaLISA™ SureFire® Ultra™ Human and Mouse Total LATS1 assay is a sandwich immunoassay for quantitative detection of total LATS1 in cellular lysates using Alpha Technology.
Large Tumor Suppressor Kinase 1 (LATS1) is a serine/threonine kinase and core component of the Hippo signaling pathway that regulates organ size and tumor suppression. LATS1 is activated by upstream kinases MST1/2 through phosphorylation, leading to autophosphorylation and full activation. Activated LATS1 phosphorylates YAP and TAZ, promoting their cytoplasmic retention and degradation, preventing transcriptional activation of growth-promoting genes. Loss of LATS1 function leads to YAP/TAZ hyperactivation and tumor development in multiple tissues. LATS1 is an important target for understanding tissue growth control and developing therapies for cancers with Hippo pathway dysregulation.
The AlphaLISA SureFire Ultra Human and Mouse Total LATS1 is a sandwich immunoassay for the quantitative detection of total LATS1 in cellular lysates, using Alpha Technology.
Formats:
AlphaLISA SureFire Ultra kits are compatible with:
AlphaLISA SureFire Ultra kits can be used for:
The Total-AlphaLISA SureFire Ultra assay measures the expression level of a protein target in a cell lysate.
The Total-AlphaLISA SureFire Ultra assay uses two antibodies which recognize two different distal epitopes on the targeted protein. AlphaLISA assays require two bead types: Acceptor and Donor beads. Acceptor beads are coated with a proprietary CaptSure™ agent to specifically immobilize the assay specific antibody, labeled with a CaptSure tag. Donor beads are coated with streptavidin to capture one of the detection antibodies, which is biotinylated. In the presence of targeted protein, the two antibodies bring the Donor and Acceptor beads in close proximity whereby the singlet oxygen transfers energy to excite the Acceptor bead, allowing the generation of a luminescent Alpha signal. The amount of light emission is directly proportional to the quantity of protein present in the sample.
The two-plate protocol involves culturing and treating the cells in a 96-well plate before lysis, then transferring lysates into a 384-well OptiPlate™ plate before the addition of Total-AlphaLISA SureFire Ultra detection reagents. This protocol permits the cells viability and confluence to be monitored. In addition, lysates from a single well can be used to measure multiple targets.
Detection of Total target protein with AlphaLISA SureFire Ultra reagents can be performed in a single plate used for culturing, treatment, and lysis. No washing steps are required. This HTS designed protocol allows for miniaturization while maintaining AlphaLISA SureFire Ultra quality.
A549 and PANC-1 cells were seeded in a 96-well plate (40,000 cells/well) in complete medium and incubated overnight at 37°C, 5% CO2. The cells were treated with increasing concentrations of NIBR-LTSi for 4 hours.
After treatment, the cells were lysed with 50 µL of Lysis Buffer for 10 minutes at RT with shaking (350 rpm). LATS1 Phospho (Thr1079) and Total levels were evaluated using respective AlphaLISA SureFire Ultra assays. For the detection step, 10 µL of cell lysate (approximately 8,000 cells) was transferred into a 384-well white OptiPlate, followed by 5 µL of Acceptor mix and incubated for 1 hour at RT. Finally, 5 µL of Donor mix was then added to each well and incubated for 1 hour at RT in the dark. The plate was read on an Envision using standard AlphaLISA settings.
NIBR-LTSi treatment resulted in increased LATS1 phosphorylation and decreased levels of Total LATS1.
PANC-1 cells were seeded in a 96-well plate (40,000 cells/well) in complete medium and incubated overnight at 37°C, 5% CO2. The cells were treated with increasing concentrations of Calyculin for 2 hours.
After treatment, the cells were lysed with 50 µL of Lysis Buffer for 10 minutes at RT with shaking (350 rpm). LATS1 Phospho (Thr1079) and Total levels were evaluated using respective AlphaLISA SureFire Ultra assays. For the detection step, 10 µL of cell lysate (approximately 8,000 cells) was transferred into a 384-well white OptiPlate, followed by 5 µL of Acceptor mix and incubated for 1 hour at RT. Finally, 5 µL of Donor mix was then added to each well and incubated for 1 hour at RT in the dark. The plate was read on an Envision using standard AlphaLISA settings.
Calyculin treatment resulted in increased LATS1 phosphorylation and a small decrease in the levels of Total LATS1.
LATS1 levels were assessed in THP-1 cells (WT) and LATS1 KO (Abcam, ab277862) cell lines.
Cells were lysed in Lysis Buffer at a density of 2 x 106 cells/mL for 10 minutes at RT with shaking. Lysates were diluted in Lysis Buffer and LATS1 levels were evaluated by AlphaLISA SureFire Ultra. For the detection step, 10 µL of cell lysate (20,000 cells) was transferred into a 384-well white OptiPlate, followed by 5 µL of Acceptor mix and incubated for 1 hour at RT. Finally, 5 µL of Donor mix was then added to each well and incubated for 1 hour at RT in the dark. The plate was read on an Envision using standard AlphaLISA settings.
LATS1 was detected in WT but not KO cells. This confirms the specificity of the assay for the detection of LATS1 protein.
Adherent cells were seeded at 40,000 cells/well in a 96-well culture plate in complete medium and incubated overnight at 37°C, 5% CO2. Cells were lysed with 50 µL of lysis buffer. Suspension cells were washed with HBSS and lysed with Lysis Buffer at 1 x 106 cells/mL.
LATS1 levels were evaluated by AlphaLISA SureFire Ultra. For the detection step, 10 µL of cell lysate (8,000 adherent cells or 10,000 suspension cells) were transferred into a 384-well white OptiPlate, followed by 5 µL of Acceptor Mix and incubated for 1 hour at RT. Finally, 5 µL of Donor Mix was then added to each well and incubated for 1 hour at RT in the dark. The plate was read on an Envision using standard AlphaLISA settings.
LATS1 expression was detected in a range of human and mouse cell lines.
Cell lysate was prepared from THP-1 cells treated with 100 nM Calyculin for 3 hours and lysed at 8 x 106 cells/mL.
Lysate was serially diluted in Lysis Buffer and LATS1 Phospho (Thr1079) and Total levels were evaluated by AlphaLISA SureFire Ultra. For the detection step, 10 µL of cell lysate was transferred into a 384-well white OptiPlate, followed by 5 µL of Acceptor Mix and incubated for 1 hour at RT. Finally, 5 µL of Donor Mix was then added to each well and incubated for 1 hour at RT in the dark. The plate was read on an Envision using standard AlphaLISA settings.
Approximate number of cells is indicated. The dotted line represents assay background. This assay can detect LATS1 expression in less than 2,000 cells/datapoint.
| Application |
Cell Signaling
|
|---|---|
| Automation Compatible |
Yes
|
| Brand |
AlphaLISA SureFire Ultra
|
| Detection Modality |
Alpha
|
| Product Group |
Kit
|
| Protocol Time |
2h at RT
|
| Sample Volume |
10 µL
|
| Shipping Conditions |
Shipped in Blue Ice
|
| Target |
LATS1
|
| Target Class |
Phosphoproteins
|
| Target Species |
Human
Mouse
|
| Technology |
Alpha
|
| Therapeutic Area |
Oncology
|
| Unit Size |
50,000 Assay Points
|
Are you looking for resources, click on the resource type to explore further.
Alpha technolgy enables the rapid and straightforward mesaure of virtually any target. This includes enzymes, receptor-ligand...
The definitive guide for setting up a successful AlphaLISA SureFire Ultra assay
Several biological processes are regulated by...
Discover Alpha SureFire® Ultra™ assays, the no-wash cellular kinase assays leveraging Revvity's exclusive bead-based technology...
This document includes detailed tables listing HTRF™, AlphaLISA™ SureFire® Ultra™, and Alpha SureFire® Ultra™ Multiplex assays...
Loading...
We are here to answer your questions.